

Special Issue

Tumor Microenvironment and Treatment in Uveal Melanoma

Message from the Guest Editor

Although a relatively rare disease, primary uveal melanoma (UM) is the most common malignant tumor of the eye in adults, with a yearly incidence of 5.1 cases per million. Primary UMs are effectively treated by resection, radiation therapy, or enucleation; however, more than 50% of UM patients ultimately succumb to metastases, specifically metastases of the liver. Understanding the dynamic interactions between cancer cells and their microenvironment is crucial for a better grasp on the mechanisms of cancer, including how it grows, metastasizes, and resists treatment. These assessments will contribute to the development of efficient and safe therapeutic strategies to improve patient outcomes as well as disrupt cancer cells directly and indirectly. In this Special Issue, original research articles and reviews are welcome. Papers may cover areas such as the biology of UM, its microenvironment, and treatment options, highlighting both basic and clinical aspects. I look forward to receiving your contributions.

Guest Editor

Dr. Mizue Terai

Department of Medical Oncology, Sidney Kimmel Cancer Center,
Thomas Jefferson University, 1015 Walnut Street, 1015 Curtis Building,
Philadelphia, PA 19107, USA

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/117561

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)